Therapeutic pore-forming peptides

Details Therapeutic pore-forming peptides Therapeutic pore-forming peptides

2006-08-22

2006-08-22

Canella, Karen A. (Department: 1642)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C530S300000, C530S324000, C530S402000, C530S820000, C530S822000, C530S823000, C530S825000

Reexamination Certificate

active

07094750

ABSTRACT:
A class of procytotoxic agents is characterized by a capability to kill with target cell-specificity. Such an aspect can be a pore-forming protein which has at least one lysine residue, modified by a peptide linkage to an amino acid residue, via the epsilon amino group. These agents are useful in treating cancer, especially prostate cancer.

REFERENCES:
patent: 5717064 (1998-02-01), Julian et al.
patent: 6255282 (2001-07-01), Jaynes
patent: 6265540 (2001-07-01), Isaacs et al.
patent: 97/33908 (1997-09-01), None
Liu et al (1979, Endocrinology, vol. 104, pp. 962-966, abstract only).
Blondelle et al., “Hemolytic and Antimicrobial Activites of the Twenty-Four Individual Omission Analogues of Melittin,”Biochemistry, 1991, pp. 4671-4678, vol. 30, American Chemical Society.
Dempsey et al., “Contributioon of Proline-14 to the Structure and Actions of Melittin,”FEBS Letters,1991, pp. 240-244, vol. 281, No. 1,2, Elsevier Science Publishers B.V.
Leippe et al., “Cytolytic and Antibacterial Activity of Synthetic Peptides Derived from amoebapore, the Pore-Forming Peptide ofEntamoeba Histolytica,” Proc. Natl. Acad. Sci. USA,1994, pp. 2602-2606, vol. 91.
Andrä{umlaut over ( )} et al., “Shortened Amoebapore Analogs with Enhanced Antibacterial and Cytolytic Activity,”FEBS Letters,1996, pp. 96-100, vol. 385, Federation of European Biochemical Societies.
Shai et al., “Diastereomers of Cytolysins, a Novel Class of Potent Antibacterial Peptides,”Journal Biological Chemistry,1996, pp. 7305-7308, vol. 271 No. 13, The Amercian Society for Biochemistry and Molecular Biology, Inc.
Werkmeister et al., “The Effect of Sequence Variations and Structure on the Cytolytic Activity of Melittin Peptides,”Biochimica et Biophysica Acta,1993, pp. 50-54, vol. 1157, Elsevier Science Publishers B.V.
Leippe et al., “Pore-Forming Peptide of PathogenicEntamoeba histolytica,” Proc. Natl. Acad. Sci. USA, 1991, pp. 7659-7663, vol. 88.
Horoszewicz et al., “LNCaP Model of Human Prostatic Carcinoma1,”Cancer Research, 1983, pp. 1809-1818, vol. 43, No. 4, Dept. of Biological Resources, Roswell Park Memorial Inst. Buffalo, New York.
Pinto et al., “Prostate Specific Membrane Antigen, a Unique Glutamate Carboxpeptidase: A Review of Recent Findings,”The Prostate Journal,1999, pp. 15-26, vol. 1, No. 1, Blackwell Science, Inc.
Lopes et al., “Immunohistochemical and Pharmacokinetic Characterization of the Site-Specific Immunoconjugate CYT-356 Derived from Antiprostate Monoclonal Antibody,”Cancer Research,1990, pp. 6423-6429, vol. 50, American Association for Cancer Research.
Troyer et al., “Detection and Charaterization for the Prostate-Specific Membrane Antigen (PSMA) in Tissue Extracts and Body Fluids,”Int. J. Cancer,1995, pp. 552-558, vol. 62, Wiley-Liss, Inc.
Wallrapp et al., “A Novel Transmembrane Serine Protease (TMPRSS3) Overexpressed in Pancreatice Cancer1,2,”Cancer Research,2000, pp. 2602-2606, vol. 60, No. 10, American Association for Cancer Research.
Wright et al., “Expression of Prostate-Specific membrane Antigen in Normal, Benign, and Malignant Prostate Tissues,”Urol. Oncol.,1995, pp. 18-28, vol. 1, Elsevier Science Inc., New York.
Prausnitz et al., “Electroporation of Mammaliam Skin: A Mechanism to Enhance Transdermal Drug Delivery”, Proc. Natl. Acad. Sci. USA, 1993, pp. 10504-10508, vol. 90, No. 22, Medical Sciences, NlH.
Wallace et al., “Stand and Deliver: Getting Peptide Drugs into the Body”, Science, 1993, pp. 912-913, vol. 260, American Association for the Advancement of Science.
Andreu et al., “Solid-Phasae Synthesis of Cecropin A and Related Peptides”, Proc. Natl. Acad. Sci. USA, 1983, pp. 6475-6479, vol. 80, No. 21, Biochemistry, Biological Science.
Andreu et al., “N-Terminal Analogues of Cecropin A: Synthesis, Antibacterial Activity, and Confromational Properties”, Biochemistry, 1985, pp. 1683-1688, vol. 24, No. 7, American Chemical Society.
Fink et al., “Design, Synthesis and Antibacterial Activity of Cecropin-Like Model Peptides”, Int. J. Peptide Protein Res., 1989, pp. 412-421, vol. 33, No. 6, The Rockefeller University, New York, New York.
Fink et al., “The Chemical Synthesis of Cecropin D and an Analog with Enhanced Antibacterial Activity”, J. of Biological Chemistry, 1989, pp. 6260-6267, vol. 264, No. 11, American Society for Biochemistry and Molecular Biology, Inc. Rockefeller University, New York.
CH. Nagarjun Rao et al., “Role of amino groups in the biological activity of cytotoxin-3 from indian cobra venon,”Recent Adv. Toxinol. Res., (1992), 1:514-520 (XP001031413); summary p. 514, last paragraph—p. 515, paragraph 1, p. 517, paragraph 3—p. 518, paragraph 1; tables 1, 2.
S. Bourdenet et al., “The cytotoxicity of Pseudomonas exotoxin A, inactivated by modification of the cell-binding domain I, is restored when conjugated to an erythroid cell-specific targeting agent,”Cancer Letters,(1990), 50(2):121-127 (XP001031414); summary p. 124, left-hand column, paragraph 2—p. 126, right-hand column, last paragraph.
Shinne-Ren Lin et al., “Chemical modification of amino groups in cardiotoxin III from Taiwan cobra (Naja naja atra) venom,”Biochemistry and Molecular Biology International, (1993) 31(1):175-184 (XP001031369) p. 178, paragraph 1—p. 183, paragraph 1 summary.
E. Schroeder et al., “Hemolytic activity and action on the surface tension of aequeous solutions of synthetic melittins,”Experientia(1971) 27(7):764-765 (XP001031342).
Jörg Andrä et al., “Shortened amoebapore analogs with enhanced antibacterial and cytolytic activity,”FEBS Letters(1996) 385:96-100 (XP002182888) abstract, p. 97, right-hand column, paragraph 2—p. 100, right hand column, paragraph 1.
Argiolas et al., “Bombolitins, a New Class of Mast Cell Degranulating Peptides from the Venom of the Bumblebee Megabombus Pennsylvanicus”, J. of Biological Chemistry, 1985, pp. 1437-1444, vol. 260, No. 3, American Society of Biological Chemists, Inc.
Young et al., “Characterization of a Member Pore-Forming Protein FromEntamoeba histolytica”, J. Exp.Med. 1982, pp. 1677-1690, vol. 156, No. 6, The Rockefeller University Press.
Lynch et al., “An Ion-Channel Forming Protein Produced byEntamoeba histolytica”, The EMBO Journal, 1982, pp. 801-804, vol. 1, No. 7, IRL Press Limited, Oxford, England.
Young et al., “Molecular Mechanisms of Cytotoxicity Mediated byEntamoeba histolytica;Characterization of a Pore-Forming Protein (PFP)”, J. of Cellular Biochemistry, 1985, pp. 299-308, vol. 29 No. 4, Alan R. Liss, Inc.
Rosenberg et al., “Isolation, Charaterization and Partial Purification of a Transferable Membrane Channel (Amoebapore) Produced byEntamoeba histolytica”, Molecular and Biochemical Parasitology, 1989, pp. 237-248, vol. 33, No. 3, Elsevier Science Publishers B.V.
Jansson et al., “coding of Hemolysins Within the Ribosomal RNA Repeat on a Plasmid inEntamoeba histolytica”, Science, 1994, pp. 11440-11443, vol. 263, American Association for the Advancement of Science.
Woodle e tal., “Prolonged Systemic Delivery of Peptide Drugs by Long-Cirulating Liposomes: Illustration with Vasopressin in the Brattleboro Rat”, Pharmaceutical Research, 1992, vol. 9, No. 2, Plenum Press, New York.

Affiliated with

Also associated with

Rating

Therapeutic pore-forming peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic pore-forming peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic pore-forming peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3711034